SOLVE FSHD Portfolio Company Altay Therapeutics Closes $37 Million Series A Financing to Advance DX5057 for FSHD

News summary

Milestone follows nearly US$7 million in seed investment and strategic support from SOLVE FSHD VANCOUVER, British Columbia — SOLVE FSHD, a venture-philanthropy organization dedicated to accelerating therapies for facioscapulohumeral muscular dystrophy (FSHD), today celebrated th….